Updates are available Correction dated 2021-10-05

Article History

Accepted: 1 September 2021

First Online: 24 September 2021

Change Date: 5 October 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41571-021-00571-4

Competing interests

: A.F. has received personal fees from Amgen, Astellas, Bayer, Boehringer Ingelheim, Bristol Myers Squibb (BMS), Merck Sharp & Dohme (MSD), Pfizer and Roche. V.S. has received grants from and holds advisory board and/or consultant positions for Eli Lilly/Loxo Oncology. V.S. has also received research grants from Abbvie, Agensys, Alfasigma, Altum, Amgen, Bayer, Berghealth, Blueprint Medicines, Boston Biomedical, Boston Pharmaceuticals, Celgene, D3, Dragonfly Therapeutics, Exelixis, Fujifilm, GlaxoSmithKline, Idera Pharma, Incyte, Inhibrx, MedImmune, Multivir, Nanocarrier, the National Comprehensive Cancer Network, the National Cancer Institute Cancer Therapy Evaluation Program (CTEP), Northwest Biotherapeutics, Novartis, Pharmamar, Pfizer, Roche/Genentech, Takeda, The University of Texas MD Anderson Cancer Center, Turning Point Therapeutics and Vegenics; holds advisory board/consultant positions with Daiichi-Sankyo, Eisai, Helsinn, Incyte, MedImmune, Novartis, QED Pharma, Relay Therapeutics and Signant Health; has received travel funds from ASCO, ESMO, Incyte and Pharmamar; and has received educational seminar support from Medscape. A.R. has received personal fees for attending advisory board meetings from AstraZeneca, MSD and Novartis. G.L.B. has received personal fees from Boehringer Ingelheim, Janssen-Cilag and Roche. U.M. has received personal fees for participation in speakers bureaus and advisory roles from Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Merck, MSD, Roche and Thermofisher. C.R. has received funding from the Lung Cancer Research Foundation-Pfizer Grant 2019. C.R. has also received personal fees for attending advisory board meetings from ArcherDx, BMS, Boston Pharmaceuticals, Inivata, MD Serono and Novartis; fees for speakers bureau from AstraZeneca, MSD and Roche; and non-financial support from GuardantHealth through a research collaboration. A.A. has received personal fees for attending advisory board meetings from Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, MSD, Pfizer and Roche; and for speakers bureaus from AstraZeneca, Eli Lilly and MSD.